Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Research Report: Forecast (2022-27)

By Diagnosis (Blood Tests, Biopsy, Biomarker Testing, Nasopharyngolaryngoscopy, Imaging (X-ray, CT/PET Scan, MRI)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, (Docetaxel, Cisplatin, 5-Flu Read more

  • Healthcare
  • Jul 2022
  • 195
  • HC22096

Market Definition

HNSCC (Head & Neck Squamous Cell Carcinoma) is cancer that develops in mucous membranes of the mouth, throat, & nose and showcases severe symptoms like:

  • Abnormal patches or open sores in the mouth & throat
  • Unusual pain & bleeding in the mouth
  • Difficulties in breathing, etc.

The Oral Cavity, Paranasal Sinuses, Nasal Cavity, Oropharynx, Larynx, Hypopharynx, & Nasopharynx are various locations where HNSCC can occur. In case of late detection or non-treatment, it can also spread across other parts like the lungs or lymph nodes, making the situation fatal. Hence, with the criticality of addressing such health conditions, several governments & prominent biopharma companies are actively participating in various research & development activities to bring innovations in therapeutics and cater to the unmet patient needs worldwide.  

Market Insights

The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is projected to grow at around 9.5% CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the mounting prevalence of HNSCC, i.e., augmenting the demand for diagnosis & treatment and, in turn, instigating governments of different countries to increase their respective healthcare expenditures for drug developments to cater to the high unmet requirements of patients worldwide.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 9.5%
Regions Covered North America: The US, Canada, Mexico
South America: Brazil, Rest of Latin America
Europe: Germany, The UK, France, Italy, Spain, Rest of Europe
Middle East & Africa: GCC, South Africa, Rest of Middle East and Africa 
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
Key Companies Profiled AbbVie Inc., AstraZeneca PLC, Amgen Inc., Bayer AG, Bristol Myers Squibb, DFG Oncology, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Jiangsu Hengrui, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others
Unit Denominations USD Million/Billion

 

As several countries are laying out favorable policies for the research & development and clinical trials of novel drugs, the global market is observing the active participation of the leading players. The primary causes of HNSCC include smoking, alcohol consumption, HPV (Human Papillomavirus) infection for oropharyngeal cancer, & EBV (Epstein-Barr Virus) infection for nasopharyngeal cancer.

Governments worldwide are encouraging several research institutions to indulge immensely in developing effective chemotherapy & immunotherapy drugs for the treatment of HNSCC patients. Moreover, they are also spreading awareness among people about the ill effects of smoking & alcohol consumption and the availability of effective diagnosis & treatment for HNSCC. 

Additionally, they are massively investing in the oncology sector, pharmaceutical giants, cancer associations, and other organizations for the research & development associated with HNSCC therapeutics, thereby generating lucrative opportunities for the various companies participating in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market. 

Moreover, as treatments like chemotherapy are being adopted extensively by patients across different corners of the world, the demand for drugs like Docetaxel, Cisplatin, & Bleomycin, among others, is rising swiftly and, in turn, instigating the leading biopharma companies to increase their production & distribution capacities in order to cater to the high unmet patient needs

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Research Report: Forecast (2022-27)

Market Segmentation

Based on Treatment:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Docetaxel
    • Cisplatin
    • 5-Flurouracil
    • Methotrexate
    • Others (Bleomycin, etc.)
  • Immunotherapy
    • Keytruda (Pembrolizumab)
    • Opdivo (Nivolumab)
  • Targeted Therapy
    • Cetuximab
  • Others (Combination Therapy, etc.)

Among all treatments, chemotherapy is anticipated to significantly contribute to the global expansion of the Head and Neck Squamous Cell Carcinoma (HNSCC) Market during 2022-27. The therapy can be performed on HNSCC patients, either alone or in combination with other treatments, depending upon the health status & tumor. However, in most cases, multimodality therapy is followed for patients with advanced HNSCC.

Chemotherapy combined with radiation therapy, followed by palliative care, has shown positive patient outcomes while treating metastatic cancer sites. CRT (Chemo-Radiation-Therapy) is an ideal treatment for oral cavity cancers and pharynx & larynx cancers. However, if there are signs of progressive disease post the initial chemotherapeutic regimen-based treatment, immunotherapy using immune checkpoint inhibitors is considered a viable option.

The increasing drug approvals by various regulatory bodies like the Food & Drug Association (FDA) are augmenting the demand for immunotherapy as a treatment for patients with Head & Neck Squamous Cell Carcinoma. Drugs like immune checkpoint inhibitors (Keytruda (Pembrolizumab) & Opdivo (Nivolumab)) are an ideal treatment option for HNSCC after observing progressive disease after the chemo regimen. As a result of extensive use of these inhibitors for HNSCC treatment, their demand is elevating rapidly and demonstrating new product approvals worldwide, which, in turn, would positively influence the expansion of the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market in the years to come.

On the other hand, targeted therapy is gaining rapid momentum in the global market, principally on the back of the growing demand for drugs like Cetuximab, a monoclonal antibody inhibiting the Epidermal Growth Factor Receptor (EGFR) to deliver the most promising outcomes in the HNSCC treatment. These therapies are used for blocking the activation of multiple kinases, thereby resulting in cell growth inhibitions & apoptosis (a series of molecular steps in a cell that lead to its death).

Regional Landscape

Geographically, the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Of all regions globally, Asia-Pacific is anticipated to dominate the Head and Neck Squamous Cell Carcinoma (HNSCC) Market with the largest share during 2022-27. It attributes principally to the mounting prevalence of HNSCC across different countries in the region, coupled with the substantial government funding in the healthcare sector & numerous research & development activities on discovering more effective & safe therapeutics for HNSCC treatment.

Moreover, favorable policies for drug developments & clinical trials are demonstrating increasing collaborations, partnerships, and mergers & acquisitions among prominent biopharma firms & local companies for expanding their product portfolios & visibility across Asia-Pacific. Besides, rising air pollution levels and high exposure to pollutants, both organic & inorganic chemicals, are other crucial reasons behind the growing risks of HNSCC, especially in countries like China & India.

Nevertheless, the high prevalence of HNSCC across Australia & Southeast Asian countries due to the consumption of specific carcinogen-containing products further projects remunerative prospects for the Asia-Pacific Head and Neck Squamous Cell Carcinoma (HNSCC) Market through 2027.

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market study?

Frequently Asked Questions

A. The Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market is projected to witness around 9.5% CAGR during 2022-27.

A. The escalating patient pool for HNSCC, growing consumer awareness about the easy availability of its effective diagnosis & treatment, and massive healthcare expenditure by governments of different countries worldwide are the prime aspects projected to drive the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market through 2027.

A. The growing focus of biopharmaceutical companies on getting approvals for numerous immune checkpoint inhibitors for HNSCC treatment is the key trend in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market.

A. Immunotherapy is anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market over the forecast years.

A. Globally, Asia-Pacific is projected to hold a prominent share in the Head and Neck Squamous Cell Carcinoma (HNSCC) Market over the forecast years.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Trends & Insights
  4. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Regulation & Policy, By Country
  5. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Hotspot and Opportunities
  7. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Blood Tests
        2. Biopsy
        3. Biomarker Testing
        4. Nasopharyngolaryngoscopy
        5. Imaging (X-ray, CT/PET Scan, MRI)
      2. By Treatment
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
          1. Docetaxel
          2. Cisplatin
          3. 5-Flurouracil
          4. Methotrexate
          5. Others (Bleomycin, etc.)
        4. Immunotherapy
          1. Keytruda (Pembrolizumab)
          2. Opdivo (Nivolumab)
        5. Targeted Therapy
          1. Cetuximab
        6. Others (Combination Therapy, etc.)
      3. By End-User
        1. Hospitals
        2. Clinics
        3. Specialty Cancer Centers
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Head and Neck Squamous Cell Carcinoma (HNSCC) Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AbbVie Inc.
      2. AstraZeneca PLC
      3. Amgen Inc.
      4. Bayer AG
      5. Bristol Myers Squibb
      6. DFG Oncology
      7. Dr. Reddy’s Laboratories
      8. Eli Lilly and Company
      9. F. Hoffmann-La Roche AG
      10. Jiangsu Hengrui
      11. Merck & Co., Inc.
      12. Novartis International AG
      13. Pfizer Inc.
      14. Sanofi S.A.
      15. Others
  15. Disclaimer
Head and Neck Squamous Cell Carcinoma (HNSCC) Market Segmentation